Journal
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
Volume 44, Issue 5, Pages 1212-1221Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/21691401.2015.1019668
Keywords
Antisense oligonucleotide; apoptosis; Bcl-2; cancer; drug delivery; RNA interference
Categories
Funding
- Council of Scientific and Industrial Research (CSIR), New Delhi
Ask authors/readers for more resources
Bcl-2, an antiapoptotic protein, is considered as a potential target in cancer treatment since its oncogenic potential has been proven and is well documented. Antisense technology and RNA interference (RNAi) have been used to reduce the expression of the Bcl-2 gene in many types of cancer cells and are effective as adjuvant therapy along with the chemotherapeutic agents. The lack of appropriate delivery systems is considered to be the main hurdle associated with the RNAi. In this review, we discuss the antiapoptotic Bcl-2 protein, its oncogenic potential, and various approaches utilized to target Bcl-2 including suitable delivery systems employed for successful delivery of siRNA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available